obagi-systems.jpg Acne is an inflammatory disease caused by sebaceous oil glands or hair follicles . The treatment is difficult and complex since there are many factors contributing to it. Now a new innovative product has been developed by Obagi Medical Products to combat this condition. Monotherapy uses both benzoyl peroxide (BPO) and clindamycin (BenzaClin, Dermik) to fight this disease. Clinical studies have been very positive and this product has been found to be highly effective in reducing lesions.

Product features
a. It contains a combination of 5 percent benzoyl peroxide and 1 per cent clindamycin.
b. It is comparatively more effective and has less side effects.
c. Clinical trials have proved that inflammatory and noninflammatory lesions were significantly reduced in 6 to 8 week's time.
d. Side effects were erythema and dryness of the skin.
e. A burning or stinging sensation is possible during the initial phase of treatment.
f. This offer better follicular penetration.
g. Patients are discouraged from using cosmetics during the treatment period.
h. Patients are advised to stop any anti-acne medications, hydroxy acids, systemic antibiotics or topical and systemic steroids at least 2 to 4 weeks before treatment.
i. Patients are advised to stop Isotretinoin treatment at least a year before the treatment.